

Mediterranean diet adherence, testicular function and fertility

Submission date 23/12/2025	Recruitment status Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 30/12/2025	Overall study status Ongoing	<input checked="" type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 30/12/2025	Condition category Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Mediterranean Diet (MedDiet) health benefits are well-documented and several randomly allocated clinical trials (RCT) and observational studies have proven that it is effective in reducing the risk of cardiovascular diseases, diabetes, and overall mortality but no clear associations/effects were observed on testicular function and fertility outcomes. The main objective of this study is to assess the associations/effects of a MedDiet on testicular function and fertility. The study hypothesizes that adherence to a MedDiet improves testicular function and reduces the risk of infertility.

This project will be the first to observationally and prospectively assess the role of a food pattern (MedDiet) in the primary prevention of infertility by assessing the diet-testicular function-fertility axis and the possible mechanisms implicated. Built on three well-conducted cohort studies and a newly designed RCT, the MEDFERTYL project will lead to translatable dietary interventions and contribute to the paradigm shift towards precision nutrition for fertility programs.

Who can participate?

Healthy male volunteers at reproductive age (18-40 years old).

What does the study involve?

The study will assess the associations between MedDiet adherence, testicular function, and fertility using international cohorts of individuals or couples. To assess the effect of the MedDiet on testicular function (seminogram and peripheral hormone level) and possible mechanisms implicated (sperm DNA integrity, sperm chromatin condensation, and sperm methylation).

What are the possible benefits and risks of participating?

Benefits: It is possible that you may not obtain any health benefits from participating in this study. The aim of the study is to deepen knowledge of male infertility in order to improve its detection, diagnosis, and treatment. In the short term, the results obtained in the study are not expected to directly benefit the participant, but rather to benefit the general population.

Risks: The study does not involve any risk beyond that associated with blood collection. Drawing the blood sample may cause a stinging sensation at the point where the needle is inserted into the skin and may result in a small bruise that disappears after a few days. More rarely, it may cause transient dizziness.

Where is the study run from?
Carlos III Health Institute, Spain.

When is the study starting and how long is it expected to run for?
January 2026 to December 2028.

Who is funding the study?
Strategic Action in Health-Strategic Lines of Health Research, Carlos III Health Institute, Spain.

Who is the main contact?
Dr. Albert Salas-Huetos, albert.salas@urv.cat

Contact information

Type(s)
Public, Scientific, Principal investigator

Contact name
Dr Albert Salas Huetos

ORCID ID
<https://orcid.org/0000-0001-5914-6862>

Contact details
C/Sant Llorenç, 21
Reus
Spain
43201
+34 977759379
albert.salas@urv.cat

Additional identifiers

Protocol serial number
PI25/00603

Strategic Action in Health-Strategic Lines of Health Research, Carlos III Health Institute, Spain.
AES-LEIS 2024-2027

Study information

Scientific Title
Mediterranean diet adherence, testicular function and fertility

Acronym

Study objectives

Main: To assess the effects of a Mediterranean diet (MedDiet) on testicular function.

1. To assess the effect of a MedDiet, compared to the usual diet, on 1) semen parameters (primary endpoint), and 2) peripheral levels of reproductive hormones.

2. To assess the effect of a MedDiet, compared to the usual diet, on the main possible mechanism of the changes: 1) sperm DNA integrity, 2) sperm chromatin condensation, and 3) sperm methylation.

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 18/12/2025, Comité Ético de Investigación con Medicamentos IISPV (Hospital Universitario Sant Joan de Reus, Avda. Josep Laporte, 2, Reus, 43204, Spain; +34 977779946; ceim@iispv.cat), ref: 338/2025

Primary study design

Interventional

Allocation

Randomized controlled trial

Masking

Blinded (masking used)

Control

Placebo

Assignment

Parallel

Purpose

Prevention

Study type(s)

Prevention, Quality of life

Health condition(s) or problem(s) studied

Primary prevention of infertility.

Interventions

The trial will be a two-group parallel randomized single-blind intervention study of 14 weeks duration that will be performed on healthy subjects (18-40 years) who, at baseline, followed a Western-style nutritional pattern. The trial will randomly assign participants (in a 1:1 ratio using computer-assisted randomization) to one of the following two interventions: 1) changing the usual Western-style diet to a Mediterranean diet (intervention group); or 2) following the usual Western-style diet (control group).

Intervention Type

Mixed

Primary outcome(s)

1. Semen quality parameters: sperm vitality, sperm motility, sperm morphology, and sperm count and concentration measured using the CASA System according to the 2010 WHO protocols at baseline (V0) and the end of the intervention period (V3, after 14 weeks)

Key secondary outcome(s)

1. Peripheral blood levels of reproductive hormones (total testosterone (pool), free testosterone, estradiol, inhibin B, prolactin (pool), LH, FSH, and SHBG) measured using standardized protocols of the hospital and/or using ELISA at baseline (V0) and the end of the intervention period (V3, after 14 weeks)

2. Blood count, glycemic profile, lipid profile, and liver and renal function measured using standardized protocols of the hospital and/or using ELISA at baseline (V0) and the end of the intervention period (V3, after 14 weeks)

3. Plasma folate and red blood cell folate (RBCF) concentrations measured using microbiological assay with *Lactobacillus casei*, and plasma cobalamin by *Lactobacillus leichmannii* at baseline (V0) and the end of the intervention period (V3, after 14 weeks)

4. Total fasting plasma homocysteine (tHcy) measured using IMx fluorescence polarization immunoassay at baseline (V0) and the end of the intervention period (V3, after 14 weeks)

5. Riboflavin and pyridoxine status measured using erythrocyte glutathione reductase activation coefficient (EGRAC) and erythrocyte aspartate aminotransferase activation coefficient (EASTAC), respectively. Polymorphisms were determined on leukocyte-extracted DNA by matrix-assisted laser desorption/ionization/time-of-flight MS at baseline (V0) and the end of the intervention period (V3, after 14 weeks)

6. Sperm DNA integrity in semen samples: The analysis of double-stranded DNA breaks (DSB) measured using the Neutral Comet assay at baseline (V0) and the end of the intervention period (V3, after 14 weeks)

7. Sperm chromatin condensation in semen: Analysis of sperm chromatin condensation measured using labeling with chromomycin A3 (CMA3) at baseline (V0) and the end of the intervention period (V3, after 14 weeks)

8. Sperm DNA methylation in semen: Sperm DNA methylation profiles measured using pyrosequencing at baseline (V0) and the end of the intervention period (V3, after 14 weeks)

Completion date

31/12/2028

Eligibility

Key inclusion criteria

1. Healthy subjects
2. Aged 18-40 years
3. Male
4. Follow a Western-style nutritional pattern

Participant type(s)

Healthy volunteer

Healthy volunteers allowed

Yes

Age group

Adult

Lower age limit

18 years

Upper age limit

40 years

Sex

Male

Total final enrolment

0

Key exclusion criteria

1. Allergy to foods typical of the Mediterranean diet (nuts or traces thereof, extra virgin olive oil).
2. Presence of alcoholism, active drug dependence, or smoking (>5 cigarettes per day or equivalent).
3. Known history of hepatitis B or C, or HIV antibodies.
4. Any serious illness.
5. Cancer diagnosed within the last five years.
6. Active infectious disease.
7. High-grade inflammatory disease.
8. Scheduled surgery within the next 2 months after randomization.
9. Use of plant sterols, antihypertensive or antidiabetic medications, mineral supplements, fiber supplements, fish oil, or antioxidants.
10. Following vegetarian, macrobiotic, vegan, or similar diets for weight loss at the start of the study.
11. Weight loss of more than 5 kg in the past month.
12. Any type of disease in the reproductive history or vasectomy.
13. Use of medications associated with sperm abnormalities: antidepressants (paroxetine, citalopram, fluoxetine, sertraline, bupropion); calcium channel blockers (diltiazem, nifedipine); alpha-adrenergic blockers (tamsulosin, alfuzosin); antiepileptics (phenytoin, carbamazepine, valproate); antiretrovirals (HAART, saquinavir), etc.
14. Other medical or social conditions that may hinder adherence to the intervention or follow-up.

Date of first enrolment

01/01/2026

Date of final enrolment

31/12/2028

Locations

Countries of recruitment

Spain

Study participating centre

Universitat Rovira i Virgili

C/Sant Llorenç, 21

Reus

Spain

43201

Sponsor information

Organisation

Instituto de Salud Carlos III

ROR

<https://ror.org/00ca2c886>

Funder(s)

Funder type

Not defined

Funder Name

Instituto de Salud Carlos III

Alternative Name(s)

SaludISCI, InstitutodeSaludCarlosIII, Instituto de Salud Carlos III | Madrid, Spain, Carlos III

Institute of Health, Institute of Health Carlos III, Carlos III Health Institute, La misión del Instituto de Salud Carlos III (ISCI), ISCI

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

Spain

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon reasonable request to the PI: Albert Salas-Huetos (albert.salas@urv.cat).

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Statistical Analysis Plan			30/12/2025	No	No